Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn’s Disease
Reena Khanna(University of Toronto), William J. Sandborn(University of San Diego), Lisa M. Shackelton, Marco Daperno(A. O. Ordine Mauriziano di Torino), Brian G. Feagan(Western University), Edward V. Loftus(Mayo Clinic), Geert D’Haens(Amsterdam University Medical Centers), Brian Bressler(University of British Columbia), Larry Stitt(Western University), Guangyong Zou(Western University), Tanja VanViegen, Remo Panaccione(University of Calgary), John WD McDonald, Vipul Jairath(Western University)
Cited by 4
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k